Keyword: Shire

Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.

Caladrius is boosting its pipeline with a late-stage cell therapy for refractory angina.

The companies are part of a star-studded commission that is working on a road map for improving outcomes in rare diseases.

The investment equips Rani to step up manufacturing of its robotic, oral biologic delivery pill in anticipation of moving the devices into the clinic.

The asset is a recombinant protein designed by AB Biosciences to improve on existing intravenous immunoglobulin therapies.

Rare disease biopharma Shire has kick-started a new mandatory open-access program for research manuscripts to journals it has funded.

Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.

The series C tees up Scholar Rock to find out whether its myostatin blocker can best one-time rivals from companies including Novartis.

We all love a top 10: It serves as a definitive "best of the best," and sometimes a look at the top of the chart can reflect the state of an industry.

The project is built upon a device Rani designed to enable the oral delivery of proteins and other molecules that are currently injected.